Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Подагра в практике врача первичного звена: профилактика, диагностика и лечение
Подагра в практике врача первичного звена: профилактика, диагностика и лечение
Мясоедова С.Е. Подагра в практике врача первичного звена: профилактика, диагностика и лечение. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2018; 2: 30–35. DOI: 10.26442/2414357X.2018.2.000055
DOI: 10.26442/2414357X.2018.2.000055
________________________________________________
DOI: 10.26442/2414357X.2018.2.000055
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье суммированы современные подходы к выявлению и коррекции гиперурикемии, диагностике и лечению подагры. Представлена современная стратегия лечения подагры, включающая уратснижающую терапию аллопуринолом и фебуксостатом. Показаны особенности фармакологических эффектов фебуксостата. Дана оценка эффективности и безопасности фебуксостата на основании результатов клинических исследований.
Ключевые слова: подагра, профилактика, диагностика, лечение, гиперурикемия, уратснижающая терапия, фебуксостат, аллопуринол.
Key words: gout, prevention, diagnosis, treatment, hyperuricemia, urat-lowering therapy, febuxostat, allopurinol.
Ключевые слова: подагра, профилактика, диагностика, лечение, гиперурикемия, уратснижающая терапия, фебуксостат, аллопуринол.
________________________________________________
Key words: gout, prevention, diagnosis, treatment, hyperuricemia, urat-lowering therapy, febuxostat, allopurinol.
Полный текст
Список литературы
1. Елисеев М.C. Подагра. В кн.: Российские клинические рекомендации. Ревматология. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2017; с. 253–64. / Eliseev M.C. Podagra. V kn.: Rossiiskie klinicheskie rekomendatsii. Revmatologiia. Pod red. E.L.Nasonova. M.: GEOTAR-Media, 2017; s. 253–64. [in Russian]
2. Сhoi HK. Epidemiology and classification of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1591–7.
3. Галушко Е.А. Медико-социальная значимость ревматических заболеваний. Дис. … д-ра мед. наук. М., 2011. / Galushko E.A. Mediko-sotsial'naia znachimost' revmaticheskikh zabolevanii. Dis. … d-ra med. nauk. M., 2011. [in Russian]
4. Janson RW. Gout. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017;
p. 337–45.
5. Dalbeth N, McLean L. Etiology and pathogenesis of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1598–603.
6. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). СПб., 2017. / Diagnostika, lechenie, profilaktika ozhireniia i assotsiirovannykh s nim zabolevanii (natsional'nye klinicheskie rekomendatsii). SPb., 2017. [in Russian]
7. Sclezinger N. Clinical fetures of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1610–2.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29–42.
9. Terkeltaub R. Management of gout and hyperurikemia. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1613–20.
10. Keenan RT Limitation of the current standarts of care for treating gout and crystal deposition in the primary care setting: a rewiev. Clin Ther 2017; 39 (2): 430–40.
11. Kanna D, Fitzerald JD, Khanna PP et al. 2012 American Colledge of Rheumatology guidelines for management of gout. Part I: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64 (10): 1431–46.
12. National Center for Biotechnology Information. Pub Chem Compaund Database; CID=134018. http://pubchem.ncbi.nim.nih.gov/compaund/134018
13. Finger DR. Hypouremic agents and colchicine. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017; p. 645–51.
14. Edwards NL. Febuxost: a new treatment for hyperuricemia in gout. Rheumatology 2009; 48 (Suppl. 2): 15–9.
15. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653.
16. Kydd AS, Seth R, Buchbinder R et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl 2014; 92: 33–41.
17. Echteld IA, Durme С, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheumatol Suppl 2014; 92: 48–54.
18. Sriranganathan MK, Vinik O, Falzon L et al. Interventions for Tophi in Gout: A Cochrane Systematic Literature Review. J Rheumatol Suppl 2014; 92: 63–9.
19. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48: 188–94.
20. Yamanaka H, Tamaki S, Ide Y et al. Stepwise dose increase of febuxostat is comparable with colchicines prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis 2017. pii: annrheumdis-2017-211574. DOI: 10.1136/annrheumdis-2017-211574 [Epub ahead of print]
21. Choi H, Neogy T, Stamp L et al. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 2018; 70 (11): 1702–9.
22. Sheer R, Null KD, Szymanski KA et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 2017; 9: 629–39.
23. Барскова В.Г., Елисеев М.С., Денисов И.С. и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Науч.-практ. ревматология. 2012; 50 (6): 15–8. / Barskova V.G., Eliseev M.S., Denisov I.S. i dr. Chastota metabolicheskogo sindroma i soputstvuiushchikh zabolevanii u bol'nykh podagroi. Dannye mnogotsentrovogo issledovaniia. Nauch.-prakt. revmatologiia. 2012; 50 (6): 15–8. [in Russian]
2. Сhoi HK. Epidemiology and classification of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1591–7.
3. Galushko E.A. Mediko-sotsial'naia znachimost' revmaticheskikh zabolevanii. Dis. … d-ra med. nauk. M., 2011. [in Russian]
4. Janson RW. Gout. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017;
p. 337–45.
5. Dalbeth N, McLean L. Etiology and pathogenesis of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1598–603.
6. Diagnostika, lechenie, profilaktika ozhireniia i assotsiirovannykh s nim zabolevanii (natsional'nye klinicheskie rekomendatsii). SPb., 2017. [in Russian]
7. Sclezinger N. Clinical fetures of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1610–2.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29–42.
9. Terkeltaub R. Management of gout and hyperurikemia. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1613–20.
10. Keenan RT Limitation of the current standarts of care for treating gout and crystal deposition in the primary care setting: a rewiev. Clin Ther 2017; 39 (2): 430–40.
11. Kanna D, Fitzerald JD, Khanna PP et al. 2012 American Colledge of Rheumatology guidelines for management of gout. Part I: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64 (10): 1431–46.
12. National Center for Biotechnology Information. Pub Chem Compaund Database; CID=134018. http://pubchem.ncbi.nim.nih.gov/compaund/134018
13. Finger DR. Hypouremic agents and colchicine. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017; p. 645–51.
14. Edwards NL. Febuxost: a new treatment for hyperuricemia in gout. Rheumatology 2009; 48 (Suppl. 2): 15–9.
15. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653.
16. Kydd AS, Seth R, Buchbinder R et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl 2014; 92: 33–41.
17. Echteld IA, Durme С, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheumatol Suppl 2014; 92: 48–54.
18. Sriranganathan MK, Vinik O, Falzon L et al. Interventions for Tophi in Gout: A Cochrane Systematic Literature Review. J Rheumatol Suppl 2014; 92: 63–9.
19. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48: 188–94.
20. Yamanaka H, Tamaki S, Ide Y et al. Stepwise dose increase of febuxostat is comparable with colchicines prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis 2017. pii: annrheumdis-2017-211574. DOI: 10.1136/annrheumdis-2017-211574 [Epub ahead of print]
21. Choi H, Neogy T, Stamp L et al. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 2018; 70 (11): 1702–9.
22. Sheer R, Null KD, Szymanski KA et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 2017; 9: 629–39.
23. Barskova V.G., Eliseev M.S., Denisov I.S. i dr. Chastota metabolicheskogo sindroma i soputstvuiushchikh zabolevanii u bol'nykh podagroi. Dannye mnogotsentrovogo issledovaniia. Nauch.-prakt. revmatologiia. 2012; 50 (6): 15–8. [in Russian]
2. Сhoi HK. Epidemiology and classification of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1591–7.
3. Галушко Е.А. Медико-социальная значимость ревматических заболеваний. Дис. … д-ра мед. наук. М., 2011. / Galushko E.A. Mediko-sotsial'naia znachimost' revmaticheskikh zabolevanii. Dis. … d-ra med. nauk. M., 2011. [in Russian]
4. Janson RW. Gout. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017;
p. 337–45.
5. Dalbeth N, McLean L. Etiology and pathogenesis of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1598–603.
6. Диагностика, лечение, профилактика ожирения и ассоциированных с ним заболеваний (национальные клинические рекомендации). СПб., 2017. / Diagnostika, lechenie, profilaktika ozhireniia i assotsiirovannykh s nim zabolevanii (natsional'nye klinicheskie rekomendatsii). SPb., 2017. [in Russian]
7. Sclezinger N. Clinical fetures of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1610–2.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29–42.
9. Terkeltaub R. Management of gout and hyperurikemia. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1613–20.
10. Keenan RT Limitation of the current standarts of care for treating gout and crystal deposition in the primary care setting: a rewiev. Clin Ther 2017; 39 (2): 430–40.
11. Kanna D, Fitzerald JD, Khanna PP et al. 2012 American Colledge of Rheumatology guidelines for management of gout. Part I: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64 (10): 1431–46.
12. National Center for Biotechnology Information. Pub Chem Compaund Database; CID=134018. http://pubchem.ncbi.nim.nih.gov/compaund/134018
13. Finger DR. Hypouremic agents and colchicine. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017; p. 645–51.
14. Edwards NL. Febuxost: a new treatment for hyperuricemia in gout. Rheumatology 2009; 48 (Suppl. 2): 15–9.
15. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653.
16. Kydd AS, Seth R, Buchbinder R et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl 2014; 92: 33–41.
17. Echteld IA, Durme С, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheumatol Suppl 2014; 92: 48–54.
18. Sriranganathan MK, Vinik O, Falzon L et al. Interventions for Tophi in Gout: A Cochrane Systematic Literature Review. J Rheumatol Suppl 2014; 92: 63–9.
19. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48: 188–94.
20. Yamanaka H, Tamaki S, Ide Y et al. Stepwise dose increase of febuxostat is comparable with colchicines prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis 2017. pii: annrheumdis-2017-211574. DOI: 10.1136/annrheumdis-2017-211574 [Epub ahead of print]
21. Choi H, Neogy T, Stamp L et al. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 2018; 70 (11): 1702–9.
22. Sheer R, Null KD, Szymanski KA et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 2017; 9: 629–39.
23. Барскова В.Г., Елисеев М.С., Денисов И.С. и др. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Науч.-практ. ревматология. 2012; 50 (6): 15–8. / Barskova V.G., Eliseev M.S., Denisov I.S. i dr. Chastota metabolicheskogo sindroma i soputstvuiushchikh zabolevanii u bol'nykh podagroi. Dannye mnogotsentrovogo issledovaniia. Nauch.-prakt. revmatologiia. 2012; 50 (6): 15–8. [in Russian]
________________________________________________
2. Сhoi HK. Epidemiology and classification of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1591–7.
3. Galushko E.A. Mediko-sotsial'naia znachimost' revmaticheskikh zabolevanii. Dis. … d-ra med. nauk. M., 2011. [in Russian]
4. Janson RW. Gout. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017;
p. 337–45.
5. Dalbeth N, McLean L. Etiology and pathogenesis of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1598–603.
6. Diagnostika, lechenie, profilaktika ozhireniia i assotsiirovannykh s nim zabolevanii (natsional'nye klinicheskie rekomendatsii). SPb., 2017. [in Russian]
7. Sclezinger N. Clinical fetures of gout. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1610–2.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76 (1): 29–42.
9. Terkeltaub R. Management of gout and hyperurikemia. In: Rheumatology. Ed. by M.C.Hochberg et al. Seventh ed. Philadelphia, PA: Elsevier, Inc., 2019; p. 1613–20.
10. Keenan RT Limitation of the current standarts of care for treating gout and crystal deposition in the primary care setting: a rewiev. Clin Ther 2017; 39 (2): 430–40.
11. Kanna D, Fitzerald JD, Khanna PP et al. 2012 American Colledge of Rheumatology guidelines for management of gout. Part I: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64 (10): 1431–46.
12. National Center for Biotechnology Information. Pub Chem Compaund Database; CID=134018. http://pubchem.ncbi.nim.nih.gov/compaund/134018
13. Finger DR. Hypouremic agents and colchicine. In: West SG. Rheumatology secrets. Third ed. Elsevier Mosby, 2017; p. 645–51.
14. Edwards NL. Febuxost: a new treatment for hyperuricemia in gout. Rheumatology 2009; 48 (Suppl. 2): 15–9.
15. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 2012; 11: CD008653.
16. Kydd AS, Seth R, Buchbinder R et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl 2014; 92: 33–41.
17. Echteld IA, Durme С, Falzon L et al. Treatment of Gout Patients with Impairment of Renal Function: A Systematic Literature Review. J Rheumatol Suppl 2014; 92: 48–54.
18. Sriranganathan MK, Vinik O, Falzon L et al. Interventions for Tophi in Gout: A Cochrane Systematic Literature Review. J Rheumatol Suppl 2014; 92: 63–9.
19. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48: 188–94.
20. Yamanaka H, Tamaki S, Ide Y et al. Stepwise dose increase of febuxostat is comparable with colchicines prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis 2017. pii: annrheumdis-2017-211574. DOI: 10.1136/annrheumdis-2017-211574 [Epub ahead of print]
21. Choi H, Neogy T, Stamp L et al. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 2018; 70 (11): 1702–9.
22. Sheer R, Null KD, Szymanski KA et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 2017; 9: 629–39.
23. Barskova V.G., Eliseev M.S., Denisov I.S. i dr. Chastota metabolicheskogo sindroma i soputstvuiushchikh zabolevanii u bol'nykh podagroi. Dannye mnogotsentrovogo issledovaniia. Nauch.-prakt. revmatologiia. 2012; 50 (6): 15–8. [in Russian]
Авторы
С.Е.Мясоедова*
ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России. 153000, Россия, Иваново, Шереметевский пр-т, д. 8
*msemee@mail.ru
Ivanovo State Medical Academy of the Ministry of Health of the Russian Federation. 153000, Russian Federation, Ivanovo, Sheremetevskii pr-t, d. 8
*msemee@mail.ru
ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России. 153000, Россия, Иваново, Шереметевский пр-т, д. 8
*msemee@mail.ru
________________________________________________
Ivanovo State Medical Academy of the Ministry of Health of the Russian Federation. 153000, Russian Federation, Ivanovo, Sheremetevskii pr-t, d. 8
*msemee@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.